Opinion|Videos|March 31, 2025
FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach
Panelists discuss how the FLAURA, FLAURA2, and MARIPOSA trials have reshaped first-line therapy for EGFR-mutant non–small cell lung cancer. FLAURA established osimertinib as superior to first-generation tyrosine kinase inhibitors. FLAURA2 showed added benefit with chemotherapy. MARIPOSA highlighted amivantamab-lazertinib as a strong alternative, refining treatment choices.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you walk us through how the FLAURA, FLAURA2, and MARIPOSA data have influenced your approach to first-line therapy? What aspects of these trials were most compelling?
- FLAURA: Ramalingam SS, et al. ESMO 2019. Abstract LBA5_PR. J. Soria, FLAURA_NEJM_2017,
- FLAURA2: D. Planchard, FLAURA2_NEJM_2023
- MARIPOSA: M. Campelo ESMO 2024 Abstract 5M0, E. Felip ASCO 2024 Abstract 8504
Advertisement
Related to this article
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Advertisement
Advertisement
Trending on OncLive
1
RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy
2
Afami-Cel Outcomes Are Tied to MAGE-A4 Expression, Tumor Burden in Synovial Sarcoma
3
STX-001 Produces Durable Systemic Responses in PD-1–Resistant Melanoma
4
VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous Cancers
5